Skadden Arps Slate Meagher & Flom and Gibson Dunn & Crutcher have taken on lead roles in New Jersey-headquartered pharmaceutical group Merck & Co's $3 billion acquisition of Eyebiotech, an ophthalmology-focused drug development company in the U.K.